News >

Tripathy Discusses Developments in HR+ Breast Cancer

Caroline Seymour
Published: Tuesday, Aug 14, 2018

Debu Tripathy, MD

Debu Tripathy, MD

Although existing therapies are prolonging progression-free survival (PFS), the debate as to what frontline endocrine therapy to use and whether to partner it with a CDK 4/6 inhibitor in patients with hormone receptor (HR)-positive breast cancer continues to evolve, explained Debu Tripathy, MD.

State of the Science Summit™ on Breast Cancer, Tripathy, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tracked the evolution of treatment of patients with metastatic HR-positive breast cancer.

OncLive: How has the management of advanced HR-positive breast cancer evolved?

Tripathy: This an area that has evolved a lot in the last few years. The most important thing about treating patients with metastatic HR-positive breast cancer is to confirm the histology at the time of initial diagnosis. You want to make sure that the patient truly has breast cancer metastasis depending on where the easiest lesion to biopsy is. That may be in the lung, the liver, or sometimes in the bone. It’s also important to check the estrogen, progesterone, and HER2 receptors since that can sometimes change from what the primary tumor was. Of course, it also serves as a confirmatory diagnosis for patients who present with metastatic breast cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication
x